As we enter 2026, we want to take a moment to reflect on what has been a truly impactful year at Cortechs.ai. In 2025, our focus on clinically validated, quantitative imaging continued to translate into real-world adoption, measurable growth, and meaningful support for clinicians caring for patients with complex neurologic and oncologic disease. 

A Year of Scale and Clinical Momentum 

In 2025 alone, more than 350,000 NeuroQuant scans were processed worldwide — a milestone that reflects the growing trust in quantitative MRI and the expanding role of objective imaging biomarkers in routine clinical care. 

Utilization grew steadily throughout the year, culminating in an approximately 26% increase in monthly NeuroQuant usage from the beginning to the end of 2025. This growth reflects increasing clinical demand as more sites, specialties, and care teams integrate quantitative imaging into everyday workflows. 

Expanding Clinical Capabilities Across the Brain and Beyond 

NeuroQuant Brain Tumor has long been FDA cleared for gliomas, and in 2025, Cortechs.ai expanded its capabilities to support both brain metastases (METs) and meningiomas, broadening its utility in neuro-oncology. This expansion enables clinicians to more comprehensively quantify tumor burden and monitor change over time — supporting informed treatment planning and longitudinal assessment across a wider range of tumor types. 

Beyond neuroimaging, OnQ Prostate continued to support prostate cancer assessment by leveraging advanced MRI analytics to help clinicians better characterize disease and support diagnostic confidence. Together, NeuroQuant and OnQ Prostate reflect Cortechs.ai’s broader commitment to delivering quantitative, AI-driven tools across multiple disease areas where imaging plays a critical role in care decisions. 

Alongside continued use across Alzheimer’s disease, multiple sclerosis, traumatic brain injury, epilepsy, and other neurologic conditions, these advances underscore our mission to address clinically meaningful questions across the full spectrum of imaging-driven medicine. 

Advancing Toward Multimodal and PET Quantification 

Another defining theme of 2025 was continued progress in quantitative PET imaging, including amyloid, tau, and FDG PET. As disease-modifying therapies become more prevalent, the need for standardized, reproducible PET quantification has never been greater. 

Looking ahead to 2026, we are excited about the anticipated availability of NeuroQuant PET for clinical use, pending FDA clearance. This milestone represents an important step toward expanding quantitative imaging beyond MRI and supporting diagnosis, treatment monitoring, and longitudinal care through multimodal analytics. 

Built on Evidence, Trust, and Partnership 

Throughout the year, Cortechs.ai continued to invest deeply in regulatory rigor, peer-reviewed validation, and close collaboration with clinical partners. Our goal remains unchanged: to deliver AI tools that are transparent, clinically grounded, and designed to integrate seamlessly into real-world clinical environments. 

Looking Ahead to 2026 

As we move forward, our focus remains on: 

• Expanding multimodal analytics, bringing MRI and PET together in clinically intuitive ways 

• Supporting neurodegenerative disease management, including treatment response and safety monitoring 

• Advancing neuro-oncology and prostate imaging with quantitative, AI-driven insights 

• Maintaining the highest standards of evidence generation, regulatory excellence, and responsible AI deployment 

Thank You 

To our customers, collaborators, and clinical partners: thank you for your trust and partnership. To our team: your dedication to scientific rigor and patient impact continues to drive everything we do. 

We look forward to building on this momentum in 2026. 

Happy New Year from all of us at Cortechs.ai.